Drug
Tigulixostat clinical trials
Also written LC350189.
- studies test it
- 9
- open now
- 0
- in phase 3
- 3
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
Studies by the year they started
9 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 1
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
- Gout
- 4
Who runs them
Industry 9 · Other 0
LG Chem (7) · Innovent Biologics Technology Limited (Shanghai R&D Center) (1) · LG Life Sciences (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tigulixostat is read from its arms, and is right about nine times in ten.
Testing it · 9
- Tigulixostat (IBI128) vs Febuxostat in GoutActive, not recruitingPhase 3Innovent Biologics Technology Limited (Shanghai R&D Center)NCT07414394Written as Tigulixostat
- A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With HyperuricemiaCompletedPhase 2LG ChemNCT03934099Written as LC350189 formulated capsule
- Tigulixostat, Phase 3 Study, Placebo Controlled in Gout PatientsCompletedPhase 3LG ChemNCT05586958Written as Tigulixostat
- Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout PatientsCompletedPhase 3LG ChemNCT05586971Written as Tigulixostat
- Effect of Tigulixostat on the Pharmacokinetics of TheophyllineCompletedPhase 1LG ChemNCT06189404Written as Tigulixostat
- Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female SubjectsCompletedEarly Phase 1LG ChemNCT04966325Written as LC350189 200mg
- Renal PK Study of LC350189CompletedPhase 1LG ChemNCT04066712Written as LC350189 200 mg
- Mass Balance Study of [14C]LC350189 in Healthy VolunteersCompletedPhase 1LG ChemNCT04070846Written as [14C] LC350189
- Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189CompletedPhase 1LG Life SciencesNCT01361646Written as LC350189
As the comparator · 1 — what is tested is compared with tigulixostat
Codes
What other systems call tigulixostat · ClinicalTrials.gg INT018401
- UNII (FDA) WZ0PYQ6VLUTIGULIXOSTATOne source FDA
- NCI Thesaurus C179126TigulixostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WZ0PYQ6VLU | TIGULIXOSTAT | One source FDA |
| NCI Thesaurus | C179126 | Tigulixostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.